Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positi...

Full description

Bibliographic Details
Main Authors: Julie A. Vendrell, Jérôme Solassol, Balázs Győrffy, Paul Vilquin, Marta Jarlier, Caterina F. Donini, Laurent Gamba, Thierry Maudelonde, Philippe Rouanet, Pascale A. Cohen
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Pharmacology
Subjects:
breast cancer
ZNF217
endocrine therapy
clinical response
predictive biomarker
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01581/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01581/full

Similar Items